methylation of adenine residues in the 23S ribosomal RNA (rRNA) peptidyl transferase center, domain 5, and is the result of the ermAM gene encoding the erythromycin-ribosomal methylase. 11, 12 The methylation blocks the binding of macrolide, lincosamide (eg, clindamycin), and streptogramin B (eg, quinupristin/dalfopristin) antibiotics. The MLS B phenotype is associated with very high macrolide MICs (Ͼ64 µg/ mL) and resistance to clindamycin. This phenotype is often associated with resistance to tetracyclines and chloramphenicol, as genes encoding this resistance phenotype can be clustered on conjugative and composite transposons. 10 Other reported mechanisms of erythromycin resistance are rare 10, 13 ; therefore, the resistance phenotypes described above correlate well with genetic subtype. 14 Resistance phenotypes may have relevance for clinicians; some have postulated that MICs of M phenotype strains are in a range where pneumonia patients may respond to newer macrolides, 15 whereas MICs of MLS B phenotype strains clearly are in a range where treatment failures could occur. Gay et al 16 reported that increases in the proportion of pneumococci with M phenotype explained the increase in macrolide resistance. The study also noted that the macrolide MICs of M phenotype isolates were increasing. We examined trends of macrolide resistance among invasive S pneumoniae across the United States, trends in macrolide use, the prevalence of strains with M and MLS B phenotypes, factors associated with macrolide resistance, and MICs of macrolide-resistant isolates.
METHODS
From 1995 to 1999, the Active Bacterial Core surveillance (ABCs) system conducted continuous active, laboratory-based surveillance for invasive S pneumoniae in 30 counties (15.4 Isolates were defined as susceptible, intermediate, or resistant to agents tested according to National Committee for Clinicial Laboratory Standards definitions. 18 We defined an isolate as being macrolide-resistant if it was intermediate or resistant to a particular agent. Erythromycin-resistant isolates (MIC Ͼ0.5 µg/mL) were further classified as having either M or MLS B phenotype. Isolates that were erythromycin-resistant and clindamycin-susceptible were classified as M phenotype, and those that were both erythromycin-and clindamycin-resistant were classified as MLS B phenotype.
14 Statistical analyses were conducted using SAS version 6 (SAS Institute Inc, Cary, NC) statistical software. We used the 2 test to compare proportions and 2 test for trend with temporal analyses. PϽ.05 was considered statistically significant. Cumulative incidence rates for 1999 were calculated using 1999 population estimates from the US Census Bureau. Data for macrolide prescriptions in the United States were obtained from the National Ambulatory Medical Care Survey/ National Hospital Ambulatory Medical Care Survey conducted by the National Center for Health Statistics at the Centers for Disease Control and Prevention.
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We determined odds ratios for groups at risk for macrolide-resistant infections in 1999 using multivariable logistic regression modeling. We constructed 2 logistic regression models: (1) erythromycin-susceptible vs M phenotype and (2) erythromycin-susceptible vs MLS B phenotype. The dependent (outcome) variable was erythromycin susceptibility and the independent (predictor) variables included ABCs site, age group, race, and penicillin susceptibility. We assessed colinearity and 2-way interactions for all variables in the final multivariable model. The proportion of isolates with M phenotype increased from 7.4% in 1995 to 16 .5% in 1999 (PϽ.001) and accounted for the overall increase seen in macrolide resistance. An increase in the proportion of isolates with M phenotype was seen for children younger than 5 years and persons 5 years or older (FIGURE 1A and Figure 1B) . The erythromycin MIC 50 increased in M phenotype isolates from 4 µg/mL in 1995 to 8 µg/mL in 1999. During the 5-year period, the proportion of isolates with MLS B phenotypes remained stable (3.4% in 1995 and 3.7% in 1999).
RESULTS

Macrolide Use, 1993-1999
The number of macrolide prescriptions increased significantly (13%) from approximately 17.7 million prescriptions (69 prescriptions/1000 persons) in 1993 to approximately 21.2 million prescriptions (78 prescriptions/1000 persons) in 1999 (P=.01). The most dramatic increases were among children younger than 5 years, in whom macrolide prescriptions increased 320% from 0.7 million prescriptions (37 prescriptions/1000 persons) in 1993 to approximately 3.1 million prescriptions (164 prescriptions/1000 persons) in 1999 ( Figure 1A ). In children younger than 5 years, azithromycin has comprised the majority of recent macrolide prescriptions with nearly 0.8 million prescriptions (41 prescriptions/1000 persons) in 1996 increasing to nearly 2.3 million prescriptions (120 prescriptions/1000 persons) in 1999. Total macrolide prescription rates among individuals 5 years and older was unchanged with 16.9 prescriptions (71 prescriptions/1000 persons) in 1993 and 18.1 million prescriptions (71 prescriptions/1000 persons) in 1999 ( Figure 1B ). In this group, azithromycin accounted for 3 million prescriptions (12 prescriptions/1000 persons) in 1996 and 7.8 million prescriptions (37 prescriptions/1000 persons) in 1999. Prescriptions for all antibiotics decreased 15% (535 to 450 prescriptions/ 1000 persons from 1993 to 1999, respectively) with a 20% decrease among those younger than 5 years (1408 to 1130 prescriptions/1000 persons from 1993 to 1999, respectively).
Surveillance Results, 1999
We identified 4132 invasive pneumococcal cases in the ABCs areas in 1999, of which 3620 (87.6%) isolates underwent antimicrobial susceptibility testing. S pneumoniae was isolated from patients with bacteremic pneumonia (n=1957, 54.1%), bacteremia and no focal diagnosis (n=1342, 37.1%), meningitis (n=192, 5.3%), and other diagnoses (n=129, 3.6%). Children younger than 5 years were the source for 913 (25 A multivariable analysis of independent factors associated with M phenotype found a significantly higher proportion of M phenotype isolates among children younger than 5 years than from individuals 5 years and older (PϽ.001), from whites than from blacks (PϽ.001), and from individuals living in Georgia (P=.002), Tennessee (P=.01), and Minnesota (P = .01) compared with those living in California (TABLE 1) . Decreased susceptibility to penicillin was found to be an independent factor associated with M phenotype in the multivariable model (PϽ.001).
M phenotype isolates seldom had reduced susceptibility to chloramphenicol (7.9%) or tetracycline (16.1%), but commonly had reduced susceptibility to other antimicrobial agents including penicillin (81.1%), cefotaxime (60.5%), and trimethoprim-sulfamethoxazole (87.8%) (TABLE 2). Very few of the isolates were resistant to fluoroquinolones (0.3%). In 1999, the median erythromycin MIC 50 was 8 µg/mL in all sites except Georgia and Oregon, where erythromycin MIC 50 was 16 µg/ml or greater. Ten percent of M phenotype isolates had an erythromycin MIC 50 of 16 µg/mL or greater.
Twenty-three different serotypes were found among 3617 isolates (TABLE 3) . Among the 591 isolates with M phenotype, serotypes 14 (284, 48.0%), 6A (65, 10.9%), 23F (44, 7.4%), 19F (40, 6.8%), and 6B (37, 6.3%) were the most common. These serotypes are reported as percentages of their respective phenotypes. Other countries have reported the MLS B phenotype as more common. [22] [23] [24] [25] Globally, the predominant phenotype for macrolide-resistant pneumococci varies regionally. The M phenotype is predominant in North America, 6 ,26 while several European countries have reported the dominance of MLS B phenotype. 22, 27 Differences in types of antibiotic used and prevalence of resistant clones probably account for this difference.
The observed increase in erythromycin MICs over this short time among M phenotype isolates is concerning. For maximum efficacy, an antibiotic should reach concentrations at the infection site higher than the specific antibiotic MIC in the infecting organism. It is unclear whether pneumococci with M phenotype are clinically significant, especially since newer macrolides (eg, clarithromycin and azithromycin) achieve higher concentrations intracellularly in tissue and in the epithelial lining fluid of the lung than concentrations achieved in blood. 28, 29 We found, however, that most M phenotype isolates have erythromycin MICs of at least 8 µg/mL, an MIC at which treatment failures with clarithromycin and azithromycin have been reported. 30 Therefore, careful study and surveillance of the effect of pneumococcal macrolide resistance on clinical outcome are critical to further understanding the clinical relevance of our findings.
Similar to earlier studies for penicillin resistance, 5, 7, 11 we found that M phenotype was more common among isolates from children younger than 5 years of age, of white race, and those who lived in certain geographic locations. Among children younger than 5 years, factors such as higher incidence of nasopharyngeal carriage of S pneumoniae, [31] [32] [33] [34] day care attendance, and high frequency of antibiotic use may explain higher rates of macrolide-resistant strains. Both high rates of macrolide use and increasing macrolide-resistant pneumococcal infections among young children may contribute to the spread of macrolideresistant pneumococcus throughout the population. However, children younger than 5 years account for only a small proportion of the overall use of macrolides. Although overall macrolide use did not increase among individuals 5 years and older, macrolide use in this group may also contribute selective pressure for macrolide-resistant pneumococci.
This study has a few limitations. First, we looked at phenotypic expression of macrolide resistance using clindamycin susceptibility as a marker for M or MLS B phenotype, rather than directly examining the mefE and ermAM genes. Other macrolide resistance mechanisms are rare in pneumococci and the relationship between phenotype and genotype has been confirmed. 11, 12, 16 Thus, our approximation should be adequate to describe trends. Second, the MIC panels (highest MIC Ͼ16 µg/ mL) used did not determine actual MICs for many M phenotype and the majority of MLS B phenotype isolates. We were, however, able to assess the proportion of M phenotype isolates in the range where treatment failures may occur (MIC Ն8 µg/mL). MLS B phenotype isolates typically have MICs of 64 µg/mL or greater. 10 Macrolides are important therapeutic agents. Clinical treatment guidelines for empiric therapy for community-acquired pneumonia in adults have recommended using macrolides as firstline agents. [1] [2] [3] The increasing frequency of macrolide resistance among pneumococci and increasing MICs among resistant strains suggest that these treatment recommendations may need reevaluation. Alternative antimicrobial agents for macrolide-resistant infections exist or are in development. For young children who are penicillinallergic, however, the management of respiratory tract infections may become problematic because doxycycline and fluoroquinolones are not available as alternatives for this age group.
Strategies to control increasing macrolide resistance are needed. A study in Finland demonstrated reduction in mefE-mediated resistance among Streptococcus pyogenes after a practice guideline limiting macrolide prescriptions for pharyngitis was instituted. 35 Whether significant reduction in macrolide use is achievable through campaigns promoting appropriate antibiotic use or whether reductions in use will lead to reductions in macrolide-resistant pneumococci is unknown. Total antibiotic prescriptions have decreased since 1993 among all age groups, but our data show that macrolide prescriptions have increased dramatically in children. Given the high proportion of macrolideresistant pneumococci among the pediatric population, decreasing inappro- priate antibiotic use especially with macrolides is important to the success of strategies that will reduce macrolide resistance.
The new heptavalent pneumococcalconjugate vaccine should provide coverage against most macrolideresistant pneumococcal strains. Use of this vaccine in children has the potential to significantly change the trends observed but new serotypes not covered by the vaccine may become macrolide-resistant with continued antibiotic pressure. Pneumococci are again showing their remarkable ability to adapt to their environment, and it remains our challenge to utilize macrolides and other antibiotic agents appropriately and promote rapid introduction of effective pneumococcal vaccines.
